Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review by Thangaratinam, Shakila et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Medicine
Open Access Research article
Estimation of proteinuria as a predictor of complications of 
pre-eclampsia: a systematic review
Shakila Thangaratinam*1, Arri Coomarasamy1, Fidelma O'Mahony2, 
Steve Sharp3, Javier Zamora4, Khalid S Khan1 and Khaled MK Ismail2
Address: 1Academic Unit of Obstetrics and Gynaecology, Birmingham Women's Hospital, Birmingham, B15 2TG, UK, 2Academic Unit of 
Obstetrics and Gynaecology, Keele University School of Medicine, University Hospital of North Staffordshire, Stoke-on-Trent, UK, 3NLH Specialist 
Library for ENT and Audiology, John Radcliffe Hospital, Oxford, UK and 4Clinical Biostatistics Unit, Hospital Ramón y Cajal, Department of 
Biomathematics, University Complutense of Madrid, Madrid, Spain
Email: Shakila Thangaratinam* - s.thangaratinam@bham.ac.uk; Arri Coomarasamy - arricoomar@blueyonder.co.uk; 
Fidelma O'Mahony - fidelma.o'mahony@uhns.nhs.uk; Steve Sharp - steve_sharp12@hotmail.com; Javier Zamora - javier.zamora@hrc.es; 
Khalid S Khan - k.s.khan@bham.ac.uk; Khaled MK Ismail - khaled.ismail@uhns.nhs.uk
* Corresponding author    
Abstract
Background: Proteinuria is one of the essential criteria for the clinical diagnosis of pre-eclampsia.
Increasing levels of proteinuria is considered to be associated with adverse maternal and fetal
outcomes. We aim to determine the accuracy with which the amount of proteinuria predicts
maternal and fetal complications in women with pre-eclampsia by systematic quantitative review of
test accuracy studies.
Methods: We conducted electronic searches in MEDLINE (1951 to 2007), EMBASE (1980 to
2007), the Cochrane Library (2007) and the MEDION database to identify relevant articles and
hand-search of selected specialist journals and reference lists of articles. There were no language
restrictions for any of these searches. Two reviewers independently selected those articles in
which the accuracy of proteinuria estimate was evaluated to predict maternal and fetal
complications of pre-eclampsia. Data were extracted on study characteristics, quality and accuracy
to construct 2 × 2 tables with maternal and fetal complications as reference standards.
Results: Sixteen primary articles with a total of 6749 women met the selection criteria with levels
of proteinuria estimated by urine dipstick, 24-hour urine proteinuria or urine protein:creatinine
ratio as a predictor of complications of pre-eclampsia. All 10 studies predicting maternal outcomes
showed that proteinuria is a poor predictor of maternal complications in women with pre-
eclampsia. Seventeen studies used laboratory analysis and eight studies bedside analysis to assess
the accuracy of proteinuria in predicting fetal and neonatal complications. Summary likelihood
ratios of positive and negative tests for the threshold level of 5 g/24 h were 2.0 (95% CI 1.5, 2.7)
and 0.53 (95% CI 0.27, 1) for stillbirths, 1.5 (95% CI 0.94, 2.4) and 0.73 (95% CI 0.39, 1.4) for
neonatal deaths and 1.5 (95% 1, 2) and 0.78 (95% 0.64, 0.95) for Neonatal Intensive Care Unit
admission.
Conclusion: Measure of proteinuria is a poor predictor of either maternal or fetal complications
in women with pre-eclampsia.
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Background
Pre-eclampsia is associated with increased maternal and
fetal mortality and morbidity. Proteinuria is one of the
essential criteria for the clinical definition of pre-eclamp-
sia. It is part of the fundamental investigations performed
by healthcare professionals in primary and secondary care
to monitor disease severity and predict complications in
women with pre-eclampsia. Urinalysis by visual reagent
strip tests is widely performed in antenatal clinics and in
the community by various health professionals. Total pro-
tein estimation in a 24-hour urine sample is also fre-
quently used to assess the severity of pre-eclampsia in
patients admitted to the hospital. More recently, spot
urine protein:creatinine ratio has been used to provide an
accurate quantification of 24-hour proteinuria [1]. Esti-
mation of the accuracy of the predictive value of proteinu-
ria by any of the above methods in predicting maternal
and fetal complications will aid in clinical management
by identifying the highest risk women who may need
aggressive management, and the lower risk women in
whom unnecessary interventions may be avoided.
Proteinuria occurs due to renal glomerular endotheliosis,
a manifestation of widespread endothelial damage in pre-
eclampsia [2,3]. The association between proteinuria and
adverse fetal outcomes was first highlighted by Page and
Christianson [4]. Since then, increased excretion of pro-
tein in women with pre-eclampsia has been generally
associated with adverse maternal and fetal outcomes [5-
7]. However, the primary diagnostic studies that evaluate
the association between increase in the levels of proteinu-
ria and maternal and neonatal outcomes have not gener-
ally been conducted with sufficiently large sample size to
provide precise accuracy estimates. Moreover, they vary
widely in their definition of pre-eclampsia, maternal and
fetal outcomes, the method used for measurement and
optimal cut-off levels of proteinuria. There are no system-
atic reviews exploring the accuracy of proteinuria to pre-
dict complications of pre-eclampsia. We therefore
conducted a comprehensive systematic review to obtain
precise estimates of likelihood ratios of adverse maternal
and fetal complications for various cut-off levels of pro-
teinuria in women with pre-eclampsia.
Methods
Data Sources
The review was carried out with a prospective protocol
using widely recommended methods [8-12]. We searched
MEDLINE (1951 to 2007), EMBASE (1980 to 2007),
Cochrane Library (2007) and MEDION (a database of
diagnostic test reviews set up by Dutch and Belgian
researchers) for relevant citations. A search term combina-
tion was constructed after exhaustive planning and pilot-
ing of possible search concepts capturing the relevant
population, tests and outcomes. Our search terms are
shown in Additional file 1. An initial search in Medline
yielded 11,711 citations. The search strategy was adapted
for searching in Embase to obtain a total of 19,500 cita-
tions. From this citation set, studies were selected for
inclusion in the review in a two-stage process if they stud-
ied the accuracy of proteinuria in the prediction of mater-
nal and fetal complications in women with pre-eclampsia.
The reference lists of all known primary and review arti-
cles were examined to identify cited articles not captured
by electronic searches. Language restrictions were not
applied. A comprehensive database of relevant articles
was constructed.
Study Selection
Studies which evaluated the accuracy of proteinuria in
women with pre-eclampsia for the prediction of maternal
or fetal complications were selected in a two-stage proc-
ess. We included studies that pre-specified the patients to
have pre-eclampsia, used bedside (urine dipstick) or lab-
oratory methods (24-hour protein estimation, urine pro-
tein:creatinine ratio) to measure levels of proteinuria and
assessed maternal or fetal clinical complications as out-
come. First, the electronic searches were scrutinised and
full manuscripts of all citations that were likely to meet
the predefined selection criteria were obtained. Second,
final inclusion or exclusion decisions were made by the
reviewers (ST and FOM) after examination of these man-
uscripts. Studies which met the predefined and explicit
criteria regarding population, tests, outcomes and study
design (Additional file 2) were selected for inclusion in
the review. When disagreements occurred, they were
resolved by consensus (ST, KI and FOM). In cases of
duplicate publication, the most recent and complete ver-
sions were selected. There were no language restrictions.
Information was extracted from each selected article on
study characteristics, quality and accuracy results. Accu-
racy data were used to construct 2 × 2 tables of proteinuria
result (test positive if proteinuria levels were above the
threshold defined in the primary study, and test negative
if these were below the threshold) and maternal and fetal
outcomes.
Methodological quality assessment
All manuscripts meeting the selection criteria were
assessed for their methodological quality. Quality was
defined as the confidence that the study design, conduct
and analysis minimised bias in the estimation of test accu-
racy. Based on existing checklists [13,14], quality assess-
ment involved scrutinizing study design and relevant
features of the population, test and outcomes of the study.
A study was considered to be of good quality if it used a
prospective design, consecutive enrolment, full verifica-
tion of the test result with reference standard, and had
adequate test description. We excluded studies with case-BMC Medicine 2009, 7:10 http://www.biomedcentral.com/1741-7015/7/10
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control design as these are known to result in substantial
bias [13].
Data synthesis
Likelihood ratios (LRs) for positive and negative test
results were calculated for each study, separately for each
test threshold. Summary LRs were then computed where
appropriate for positive and negative test results for each
individual test threshold and for each outcome of interest.
This information is clinically more relevant than tradi-
tional summaries of accuracy such as sensitivity and spe-
cificity, as LRs allow the estimation of post-test
probabilities of various complications for women at dif-
ferent risk levels [15]. The LR indicates by how much a
given test result raises or lowers the probability of having
the disease. The higher the LR of an abnormal test, the
greater is the value of the test. Conversely, the lower the LR
of a normal test, the greater is the value of the test. An LR
of >10 or <0.1 is regarded as 'very useful' test accuracy,
whilst an LR of 5 to 10 or 0.1 to 0.2 is regarded as 'moder-
ately useful', and an LR of 2 to 5 or 0.2 to 0.5 is regarded
as 'somewhat useful'. An LR of 1 to 2 or 0.5 to 1 is only
regarded as 'little useful' and an LR of 1 as 'useless'.
Although, this categorization is useful for interpretation
of LRs, it should be noted that the value of a test may vary
depending on the pre-test probability of the condition,
and the consequences of treatment.
Heterogeneity of diagnostic odds ratio (dOR) was
assessed graphically using forest plot [16] (not shown)
and statistically using chi-squared test [17] to aid in deci-
sions on how to proceed with quantitative synthesis [18].
As, for some tests and outcomes, there was either graphi-
cal or statistically significant heterogeneity, we used ran-
dom effects model meta-analysis [17]. Where a
quantitative approach was not appropriate due to signifi-
cant clinical heterogeneity, we refrained from pooling and
the results are described narratively and the LR of mater-
nal and fetal complication estimated in each study is
reported. All statistical analyses were performed using
Meta Disc statistical package.
Results
Literature identification and study quality
Figure 1 summarizes the process of literature identifica-
tion and selection. There were 16 primary articles that met
the selection criteria including a total of 6749 women
(Figure 1) [1,19-34]. Eight articles reported estimation of
proteinuria by laboratory method only
[20,21,23,26,28,29,33,34], five by bedside dipstick uri-
nalysis only [22,24,25,30,32], two by either of the above
methods [27,31] and one by spot urine protein:creatinine
ratio [1]. The salient features (population subgroups, test
characteristics and reference standards) of each individual
study can be obtained from the authors. The definition of
pre-eclampsia differed widely between the studies. The
test threshold in individual studies for laboratory estima-
tion varied from 0.3 g/24 h to 10 g/24 h, or was reported
as an increase in proteinuria by 2 g/24 h between two
measurements. The cut-off levels for bedside urinalysis
using visual reagents ranged from 1+ to 4+ of proteinuria.
One study evaluated the accuracy of spot urine protein:
creatinine ratio for threshold levels of 500 mg/mmol and
900 mg/mmol in the prediction of maternal and fetal
complications [1]. The methodological quality of the
included studies is given in Figure 2.
Proteinuria to predict maternal outcomes
Three test accuracy studies evaluated the accuracy of pro-
teinuria in predicting eclampsia for cut off levels of 5 g/24
h, 10 g/24 h and an increase by 2 g in 24 hours [23,26].
The LR of positive test ranged from 1.7 (95% CI 0.94, 3.1)
to 2.7 (95% CI 1.1, 6.2) respectively. The negative LR
ranged from 0.41 (95% CI 0.04, 4.5) to 0.62 (95% CI
0.28, 1.4) (Figure 3).
Two studies estimated the accuracy of proteinuria in pre-
dicting placental abruption using a cut-off of increase in
level more than 2 g/24 h [23,29]. The pooled positive and
negative LRs for the above cut-off were 0.88 (95% CI 0.42,
1.86) and 1.1 (95% CI 0.75, 1.6) respectively (Figure 3).
HELLP syndrome prediction was evaluated in four test
accuracy studies [23,26,29]. The pooled estimate of LRs
for positive and negative test for a cut-off of increase in
levels more than 2 g in 24 hours were 0.86 (95% CI 0.38,
2) and 1.1 (95% CI 0.74, 1.6) respectively (Figure 3).
Proteinuria to predict fetal outcomes
Fetal, neonatal and perinatal mortality
Thirteen studies reported prediction of fetal, neonatal and
perinatal mortality using both laboratory and bedside
testing for proteinuria [1,20,21,23,26,28-30,34]. The
pooled LRs for positive and negative test for a cut-off of 5
g/24 h as reported in three studies [20,21,23] were 2 (95%
CI 1.5, 2.7) and 0.53 (95% CI 0.27, 1) respectively (Figure
4). The largest study, involving 3260 patients, that esti-
mated the prediction of stillbirths in pre-eclampsia was
conducted by Taylor et al using urine dipstick method
[35].
Neonatal deaths were evaluated in five studies for cut-off
levels of 5 g/24 h (n = 3) [20,21,26], 10 g/24 h (n = 1) [26]
and increase by 2 g in 24 h (n = 1) [23]. The pooled esti-
mates of LR+ and LR- for proteinuria threshold of 5 g/24
h were 1.5 (95% CI 0.94, 2.4) and 0.73 (95% 0.39, 1.4)
respectively.
The threshold levels of proteinuria to predict perinatal
deaths were 1 g/l, 2 g/l and 500 mg/mmol. The positive LRBMC Medicine 2009, 7:10 http://www.biomedcentral.com/1741-7015/7/10
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was 5.3 (95% CI 1.3, 22.1) and the negative LR was 0.55
(95% CI 0.14, 2.2) for cut-off levels of 500 mg/mmol [1].
Small for gestational age
Four studies assessed the accuracy of bedside urinalysis for
cut-offs of 1+, 2+ and 3+ of proteinuria in urine dipstick
[22,24,27]. The pooled positive and negative LRs for 3+ of
proteinuria were 1.6 (95% CI 1.1, 2.3) and 0.75 (95% CI
0.59, 0.96) respectively. The likelihood ratio of laboratory
estimates of proteinuria levels of 0.3 g/24 h and 0.5 g/24
h were 0.96 (95% CI 0.75, 1.2) and 1.7 (95% CI 1.1, 2.7)
for positive test and 1.09 (95% 0.63, 1.9) and 0.73 (95%
CI 0.52, 1) for negative test respectively, using the benze-
thonium chloride assay (BCA) [33]. For tests performed
on the same patients using the Bradford assay Waugh et al
report positive likelihood ratios of 1.71 (95% CI 1.0, 2.9)
and 2.79 (95% CI 1.4, 5.5) for cut-off levels of 0.3 g/24 h
and 0.5 g/24 h respectively [33].
Study selection process for systematic review of proteinuria to predict maternal and fetal complications Figure 1
Study selection process for systematic review of proteinuria to predict maternal and fetal complications.
Total citations identified from electronic searches              n= 541
Articles of accuracy of proteinuria in predicting maternal and fetal complications in 
women with pre eclampsia retrieved for detailed evaluation n=173
From electronic searches                             n= 163
From reference lists                                 n= 10
Primary articles included in systematic review                   n=16
Citations excluded after screening titles and/or abstracts: n= 378
Articles excluded with reasons
Inappropriate population                                         n=47
Data not extractable                                             n=48
Inappropriate outcome  - n=10
Lack of original data i.e. reviews or letters                    n=9
Inappropriate test  
Case control studies               
n=33
n=10
Total excluded                                                   n=157 BMC Medicine 2009, 7:10 http://www.biomedcentral.com/1741-7015/7/10
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Neonatal Intensive Care Unit (NICU) admission
NICU admission was assessed as an outcome in five stud-
ies [20,23,24,26]. The pooled positive and negative LRs
for cut-off level of 5 g/24 h were 1.5 (95% CI 1, 2) and
0.78 (955 CI 0.64, 0.95) and for levels of 10 g/24 h, the
LRs were 5.6 (95% CI 1.8, 17.4) and 0.77 (95% CI 0.69,
0.87) respectively.
Discussion
Proteinuria has usually been associated with increase in
maternal and fetal mortality and morbidity [7]. Our
review has shown that the magnitude of proteinuria in
women with pre-eclampsia is a poor predictor of the
major maternal and fetal complications.
For prediction of adverse fetal outcomes, the only statisti-
cally significant results were observed for positive test
result with LR+ ranging from 1.3 to 2.3 for cut-off levels of
5 g/24 h, 1+ and 3+ proteinuria in the prediction of still-
births [20,21,23,30]. Furthermore, we need to take into
account that three of these five test accuracy studies were
conducted more than 30 years ago [21,30]. The test was
found to be a poor predictor of neonatal and perinatal
deaths with no significant LRs for positive or negative test.
The test performed poorly as evidenced by the increase in
adverse events noticed in the test negative group com-
pared with the test positive group, as noticed in some
studies [23,28,33]. The overall low value of abnormal test
and high value of normal test implies that the test is of
'very little' clinical value.
The validity of our review findings depends on the meth-
odology of the systematic review and the quality of the
individual studies included [13]. An extensive literature
search was performed in relevant databases without any
language restrictions to minimize the possibility of miss-
ing any studies. Methodological deficiencies such as veri-
fication bias, differential use of reference standards and
case-control design did not apply to the studies in the
review, ensuring inclusion of studies of acceptable quality.
The methodological problems facing reviews of this
nature are daunting. A significant limitation of this review
is the heterogeneity noticed between individual studies
with regards to population, definition of pre-eclampsia,
method of performing the test, test thresholds, frequency
of testing, interval between the test and outcome, and ref-
erence standards. The lack of information regarding the
temporal relation between test findings and outcomes
observed and possibility of confounding by other risk fac-
tors contributing to maternal and fetal complications may
influence the observed predictive value of proteinuria for
maternal and fetal complications. The wide confidence
intervals observed for the various outcomes are a reflec-
tion of the statistical uncertainty around the results due to
the small sample size in many studies. Meta-analysis of
studies using individual patient data may conquer many
of the difficulties identified.
Conclusion
This systematic review has shown that estimation of levels
of proteinuria in women with is not a clinically useful test
to predict fetal or maternal complications. The results of
this review calls into question the commonly used prac-
tice of making clinical decisions in women with pre-
eclampsia based on the severity of proteinuria. It has high-
Quality of the included primary studies in the systematic review of accuracy of proteinuria in predicting complications in  women with pre-eclampsia Figure 2
Quality of the included primary studies in the systematic review of accuracy of proteinuria in predicting com-
plications in women with pre-eclampsia.
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lighted the need for large, well-designed prospective stud-
ies on this important question with the hope to expand
future research.
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Likelihood ratios for maternal outcomes in women with pre-eclampsia for various threshold levels of proteinuria Figure 3
Likelihood ratios for maternal outcomes in women with pre-eclampsia for various threshold levels of proteinu-
ria.
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Likelihood ratios for fetal outcomes in women with pre-eclampsia for various threshold levels of proteinuria Figure 4
Likelihood ratios for fetal outcomes in women with pre-eclampsia for various threshold levels of proteinuria.
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